Publications

Antonio Lerario from Hammer Lab viewing data

"If I have seen further than others, it is by standing on the shoulders of giants"

-Isaac Newton-

Below is a comprehensive list of Dr. Hammer's publications found in peer-reviewed journals. This does not include any articles submitted and awaiting review, non-peer-reviewed publications, abstracts, book chapters, editorships, or other media. 

Bibliography (chronological order)

  1. Hammer, G.D. & Kapp, B.S. (1986). The effects of naloxone administered into the periaqueductal gray on the shock-elicited freezing behavior in the rat. Behavioral and Neural Biology, 46(2), 189-195. PMID: 3767831 Read here

  2. Hammer, G.D., Fairchild-Huntress, V. & Low, M.J. (1990). Pituitary-specific and hormonally regulated gene expression directed by the rat proopiomelanocortin promoter in transgenic mice. Molecular Endocrinology, 4(11), 1689-1697. PMID: 2177840 Read here

  3. Hammer, G.D., Muller, G., Liu, B., Petrides, J.S., Roos, B.A. & Low, M.J. (1992). Ectopic corticotropin-releasing hormone produced by a transfected cell line chronically activates the pituitary-adrenal axis in transkaryotic rats. Endocrinology, 130(4), 1975-1985. PMID: 1312432 Read here

  4. Liu, B., Hammer, G.D., Rubinstein, M., Mortrud, M. & Low, M.J. (1992). Identification of DNA elements cooperatively activating proopiomelanocortin gene expression in the pituitary glands of transgenic mice. Molecular and Cellular Biology, 12(9), 3978-3900. PMID: 1508198 Read here

  5. Asa, S.L., Kovacs, K., Hammer, G.D., Liu, B., Roos, B.A. & Low, M.J. (1992) Pituitary corticotroph hyperplasia in rats implanted with a medullary thyroid carcinoma cell line transfected with a corticotropin-releasing hormone cDNA expression vector. Endocrinology, 131(2), 715-720. PMID: 1322279 Read here

  6. Low, M.J., Liu, B., Hammer, G.D., Rubinstein, M. & Allen, R.G. (1993). Post-translational processing of proopiomelanocortin (POMC) in mouse pituitary melanotroph tumors induced by a POMC-simian virus 40 large T antigen transgene. Journal of Biological Chemistry, 268(33), 24967-24975. PMID: 8227058 Read here

  7. Nachtigal, M.W., Horokawa, Y., Enyeart-VanHouten, D.L., Flanagan, J.N., Hammer, G.D. & Ingraham, H.A. (1998). Wilms’ Tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell, 93(3), 445-454. PMID: 9590178 Read here

  8. Hammer, G.D., Kylova, I., Zhang, Y., Darimont, B.D., Simpson, K., Weigel, N.L. & Ingraham, H.A. (1999). Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: Integration of hormone signaling in reproduction and stress. Molecular Cell, 3(4), 521-526. PMID: 10230405 Read here

  9. Hammer, G.D. & Ingraham H.A. (1999). Steroidogenic Factor-1: Its role in endocrine organ development and differentiation. Frontiers in Neuroendocrinology, 20(3), 199-223. PMID: 10433862 Read here

  10. Beuschlein, F. & Hammer, G.D. (2002). Ectopic pro-opiomelanocortin syndrome. Endocrinology and Metabolism Clinics of North America, 31(1), 191-234. PMID: 12055989 Read here

  11. Babu, P.S., Bavers, D.L., Beuschlein, F., Shah, S., Jeffs, B., Jameson, J.L. & Hammer, G.D. (2002). Interaction between Dax-1 and steroidogenic factor-1 in vivo: Increased adrenal responsiveness to ACTH in the absence of Dax-1. Endocrinology, 143(2), 665-673. PMID: 11796523 Read here

  12. Beuschlein, F., Mutch, C., Bavers, D.L., Ulrich-Lai, Y., Engeland, W.C., Keegan, C. & Hammer, G.D. (2002). Steroidogenic Factor-1 is essential for compensatory adrenal growth following unilateral adrenalectomy. Endocrinology, 143(8), 3122-3135. PMID: 12130578 Read here

  13. Keegan, C.E. & Hammer, G.D. (2002). Recent insights into Organogenesis of the adrenal cortex. Trends in Endocrinology and Metabolism, 13(5), 200-208. PMID: 12185666 Read here

  14. Kennell, J.A., O’Leary, E.E., Gummow, B.M., Hammer, G.D. & MacDougald, O.A. (2003). TCF-4N, a novel isoform of mouse TCF-4, synergizes with β-catenin to coactivate C/EBPβ and SF-1 transcription factors. Molecular and Cellular Biology, 23(15), 5366-5375. PMID: 12861022 Read here

  15. Beuschlein, F., Looyenga, B.D., Mutch, C., Bleasdale, S., Bavers, D.L., Parlow, A.F., Nilson, J.H. & Hammer, G.D. (2003). Activin induces X-zone apoptosis that inhibits luteinizing hormone-dependent adrenocortical tumor formation in inhibin-deficient mice. Molecular and Cellular Biology, 23(11), 3951-3964. PMID: 12748296 Read here 

  16. Gummow, B.M., Winnay, J.N. & Hammer, G.D. (2003). Convergence of Wnt signaling and SF-1 on transcription of the rat inhibin alpha gene. Journal of Biological Chemistry, 278(29), 26572-26579. PMID: 12732619 Read here

  17. Beuschlein, F., Looyenga, B.D., Reincke, M. & Hammer, G.D. (2004). Role of the inhibin/activin system and luteinizing hormone in adrenocortical tumorigenesis. Hormone and Metabolic Research, 36(6), 392-396. PMID: 15241730 Read here

  18. Hammer, G.D., Tyrrell, J.B., Lamborn, K.R., Applebury, C.B., Hannegan, E.T., Bell, S., Rahl, R., Lu, A. & Wilson, C.B. (2004). Transsphenoidal microsurgery for Cushing's disease: Initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism, 89(12), 6348-6357. PMID: 15579802 Read here

  19. Keegan, C.E., Hutz, J.E., Else, T., Adamska, M., Sah, S.P., Kent, A.E., Howes, J., Beamer, W.G. & Hammer, G.D. (2005). Urogenital and caudal dysgenesis in adrenocortical dysplasia (acd) mice is caused by a splicing mutation in a novel telomeric regulator. Human Molecular Genetics, 14(1), 113-123. PMID: 15537664 Read here

  20. Hammer, G.D., Parker, K.L. & Schimmer, B.P. (2005). Minireview: transcriptional regulation of adrenocortical development. Endocrinology, 146(3), 1018-1024. PMID: 15604207 Read here

  21. Schteingart, D.E., Doherty, G.M., Gauger, P.G., Giordano, T.J., Hammer, G.D., Korobkin, M. & Worden, F. (2005). Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocrine-Related Cancer, 12(3), 667-680. PMID: 16172199 Read here

  22. Park, S.Y., Meeks, J.J., Raverot, G., Pfaff, L.E., Weiss, J., Hammer, G.D. & Jameson, J.L. (2005). Nuclear receptors Sf1 and Dax1 function cooperatively to mediate somatic cell differentiation during testis. Development, 132 (10), 2415-2423. PMID: 15829514 Read here

  23. Else, T. & Hammer, G.D. (2005). Genetic analysis of adrenal absence: Agenesis and aplasia. Trends in Endocrinology and Metabolism, 16(10), 458-468. PMID: 16275119 Read here

  24. Winnay, J.N., Xu, Z., O'Malley, B.W. & Hammer, G.D. (2006). SRC-1 deficient mice exhibit altered hypothalamic-pituitary-adrenal axis function. Endocrinology. 147(3), 1322-1332. PMID: 16339206 Read here

  25. Winnay, J.N. & Hammer, G.D. (2006). Adrenocorticotropic hormone-mediated signaling cascades coordinate a cyclic pattern of steroidogenic factor 1-dependent transcriptional activation. Molecular Endocrinology. 20(1), 147-166. PMID: 16109736 Read here

  26. Hutz, J.E., Krause, A.S., Achermann, J., Vilain, E., Tauber, M., Lecointre, C., McCabe, E.R.B., Hammer, G.D. & Keegan CE. (2006). IMAGe association and congenital adrenal hypoplasia: No disease-causing mutations found in the ACD gene. Molecular Genetics and Metabolism, 88(1), 66-70. PMID: 16504561 Read here

  27. Nguyen- Martin, M. & Hammer, G.D. (2006). Pheochromocytoma: Risk groups, diagnosis and management in primary care. Hospital Physician, 42(2), 17-24. 

  28. Johnsen, I.K., Slawik, M., Shapiro, I., Hartmann, M.F., Wudy, S.A., Looyenga, B.D., Hammer, G.D., Reincke, M. & Beuschlein, F. (2006). Gonadectomy in mice of the inbred strain CE/J induces proliferation of subcapsular adrenal cells expressing gonadal marker genes. Journal of Endocrinology, 190(1), 47-57. PMID: 16837610 Read here

  29. Looyenga, B.D. & Hammer, G.D. (2006). Origin and identity of adrenocortical tumors in inhibin knockout mice: Implications for cellular plasticity in the adrenal cortex. Molecular Endocrinology, 20(11), 2848-2863. PMID: 16873442 Read here

  30. Gummow, B.M., Scheys, J.O., Cancelli, V.R. & Hammer, G.D. (2006). Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Molecular Endocrinology, 20(11), 2711-2723. PMID: 16857744

  31. Looyenga, B.D. & Hammer, G.D. (2007). Genetic removal of Smad3 from inhibin-null mice attenuates tumor progression by uncoupling extracellular mitogenic signals from the cell cycle machinery. Molecular Endocrinology, 21(10), 2440-2457. PMID: 17652186

  32. Else, T., Theisen, B.K., Wu, Y., Hutz, J.E., Keegan, CE, Hammer, G.D. & Ferguson, D.O. (2007). Tpp1/Acd maintains genomic stability through a complex role in telomere protection. Chromosome Research, 15(8), 1001-1013. PMID: 18185984

  33. Lichtenauer, U., Duchniewicz, M., Kolanczyk, M., Höflich, A., Hahner, S., Else, T., Bicknell, A.B., Zemojtel, T., Stallings, N.R., Hammer, G.D., Scheele, J. & Beuschlein, F. (2007). Pre-B-cell transcription factor 1 and steroidogenic factor 1 synergistically regulate adrenocortical growth and steroidogenesis. Endocrinology, 148(2), 693-704. PMID: 17082260

  34. Kim, A. & Hammer, G.D. (2007). Adrenocortical Cells with Stem/Progenitor Cell Properties: Recent Advances. Molecular and Cellular Endocrinology, 265-266, 10-16. PMID: 17240045

  35. Keegan, C.E., Hutz, J.E., Krause, A.S., Koehler, K., Metherell, L.A., Boikos, S., Stergiopoulos, S., Clark, A.J., Stratakis, C.A., Huebner, A., & Hammer, G.D. (2007). Novel polymorphisms and lack of mutations in the ACD gene in patients with ACTH resistance syndromes. Clinical Endocrinology, 67(2), 168-174.  PMID: 17466001

  36. Hockemeyer, D., Palm, W., Else, T., Daniels, J-P., Takai, K.K., Ye, JZ-S., Keegan, C.E., deLange, T. & Hammer, G.D. (2007). Telomere protection by mammalian Pot1 requires interaction with Tpp1. Nature Structural and Molecular Biology, 14(8), 754-761. PMID: 17632522

  37. Barlaskar, F.M. & Hammer, G.D. (2007). The molecular genetics of adrenocortical carcinoma. Reviews in Endocrine and Metabolic Disorders, 8(4), 343-348. PMID: 17934868

  38. Else, T., Giordano, T.J. & Hammer, G.D. (2008). Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. The Journal of Clinical Endocrinology & Metabolism, 93(4),1442-1449. PMID: 18198226

  39. Rui, X., Tsao, J., Scheys, J.O., Hammer, G.D. & Schimmer, B.P. (2008). Contributions of specificity protein-1 and steroidogenic factor 1 to Adcy4 expression in Y1 mouse adrenal cells. Endocrinology, 149(7), 3668-3678. PMID: 18388192

  40. White, M.L., Gauger, P.G., Doherty, G.M., Cho, K.J., Thompson, N.W., Hammer, G.D. & Miller, B.S. (2008). The role of radiologic studies in the evaluation and management of primary hyperaldosteronism. Surgery, 144(6), 926-933. PMID: 19040999

  41. Kim, A.C., Reuter, A.L., Zubair, M., Else, T., Serecky, K., Bingham, N.C., Lavery, G.G., Parker, K.L. & Hammer GD. (2008). Targeted disruption of β-catenin in Sf-1-expressing cells impairs development and maintenance of the adrenal cortex. Development, 135(15), 2593-2602. PMID: 18599507

  42. Yang, W-H., Heaton, J.H., Brevig, H., Mukherjee, S., Iñiguez-Lluhí, J.A. & Hammer, G.D. (2009). SUMOylation inhibits SF-1 activity by reducing CDK7-mediated Serine 203 phosphorylation. Molecular and Cellular Biology, 29(3), 613-625. PMID: 19015234

  43. Xu, B., Yang, W-H., Gerin, I., Hu, C-D., Hammer, G.D. & Koenig, R.J. (2009). DAX-1 and steroid receptor RNA activator (SRA) function as transcriptional coactivators for steroidogenic factor-1 in steroidogenesis. Molecular and Cellular Biology, 29(7),1719-1734 (2009). PMID: 19188450

  44. Giordano, T.J., Kuick, R., Else, T., Gauger, P.G., Vinco, M., Bauersfeld, J., Sanders, D., Thomas, D.G., Doherty, G., & Hammer, G.D. (2009). Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clinical Cancer Research, 15(2), 668-676. PMID: 19147773

  45. Barlaskar, F.M., Spalding, A.C., Heaton, J.H., Kuick, R., Kim, A.C., Thomas, D.G., Giordano, T.J., Ben-Josef, E. & Hammer, G.D. (2009). Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. The Journal of Clinical Endocrinology & Metabolism, 94(1), 204-212 (2009). PMID: 18854392         

  46. Kim, A.C., Barlaskar, F.M., Heaton, J.H., Else, T., Kelly, V.R., Krill, K.T., Scheys, J.O., Simon, D.P., Trovato, A., Yang, W-H. & Hammer, G.D. (2009). In search of adrenocortical stem and progenitor cells. Endocrine Reviews, 30(3), 241-263. PMID: 19403887

  47. Else, T., Trovato, A., Kim, A.C., Wu, Y., Ferguson, D.O., Kuick, R., Lucas, P.C. & Hammer, G.D. (2009). Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell, 15(6), 465-476. PMID: 19477426

  48. Strosberg, J.R., Hammer, G.D. & Doherty, G.M. (2009). Management of adrenocortical carcinoma. Journal of the National Comprehensive Cancer Network, 7(7), 752-758. PMID: 19635227

  49. Looyenga, B.D., Wiater, E., Vale, W. & Hammer, G.D. (2010). Inhibin-A Antagonizes TGFβ2 Signaling by down regulating cell surface expression of the TGFβ co-receptor Betaglycan. Molecular Endocrinology, 24(3), 608-620. PMID: 20160125

  50. Kelly, V.R., Xu, B., Kuick, R., Koenig, R.J. & Hammer, G.D. (2010). Dax1 upregulates OCT4 expression in mouse embryonic stem cells via LRH-1 and SRA. Molecular Endocrinology, 24(12): 2281-2291. PMID: 20943815

  51. Haluska, P., Worden, F., Olmos, D., Donghua, Y., Schteingart, D., Batzel, G.N., Paccagnella, M.L., de Bono, J.S., Gualberto, A. & Hammer, G.D. (2010). Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology, 65(4),765-773. PMID: 19649631

  52. Watson, R.L., Spalding, A.C., Zielske, S.P., Morgan, M., Kim, A.C., Bommer, G.T., Eldar-Finkelman, H., Giordano, T., Fearon, E.R., Hammer, G.D., Lawrence, T.S. & Ben-Josef, E. (2010). GSK3β and β-catenin modulate radiation cytotoxicity in pancreatic cancer. Neoplasia, 12(5), 357-365. PMID: 20454507 

  53. Garcia-Perez, J.L., Morell, M., Scheys, J.O., Kulpa, D.A., Morell, S., Carter, C.C., Hammer, G.D., Collins, K.L., O’Shea, K.S., Menendez, P. & Moran JV. (2010). Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. Nature, 466(7307),769-73. PMID: 20686575

  54. Miller, B,S,, Ammori, J.B., Gauger, P.G., Broome, J.T., Hammer, G.D. & Doherty, G.M. (2010). Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World Journal of Surgery, 34(6),1380-1385. PMID: 20372905

  55. Miller, B.S., Gauger, P.G., Hammer, G.D., Giordano, T.J. & Doherty, G.M. (2010). Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langebeck's Archives of Surgery, 395(7), 955-961. PMID: 20694732

  56. Kelly, V.R. & Hammer, G.D. (2011). LRH-1 and Nanog regulate Dax1 transcription in mouse embryonic stem cells. Molecular and Cellular Endocrinology, 332(1-2), 116-124. PMID: 20937355

  57. Wood, M.A. & Hammer, G.D. (2010). Adrenocortical stem and progenitor cells: Unifying model of two proposed origins. Molecular and Cellular Endocrinology, 336(1-2), 206-212. PMID: 21094677

  58. Dobrosotskaya, I.Y., Hammer, G.D., Schteingart, D.E., Maturen, K.E. & Worden, F.P. Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. Endocrine Practice, 17(3), e59-e62. PMID: 21454232

  59. Scheys, J.O., Heaton, J.H., & Hammer, GD. (2011). Evidence of adrenal failure in aging Dax1-deficient mice. Endocrinology, 152(9), 3430-34399. PMID: 21733829

  60. Nasonkin, I.O., Ward, R.D., Bavers, D.L., Beuschlein, F., Mortensen, A.H., Keegan, C.E., Hammer, G.D. & Camper, SA. (2011). Aged PROP1 deficient dwarf mice maintain ACTH production. PLoS ONE, 6(12), e28355. PMID: 22145038

  61. Sabolch, A., Feng, M., Griffith, K., Hammer, G.D., Doherty, G. & Ben-Josef, E. (2011). Adjuvant and definitive radiotherapy for adrenocortical carcinoma. International Journal of Radiation Oncology Biology and Physics, 80(5), 1477-1484. PMID: 20675074

  62. Simon, D.P. & Hammer, G.D. (2012). Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma. Molecular Cellular Endocrinology, 351(1), 2-11 (2012). PMID: 22266195

  63. Simon, D.P., Giordano, T.J. & Hammer, G.D. (2012). Upregulated JAG1 Enhances cell proliferation in adrenocortical carcinoma. Clinical Cancer Research, 18(9), 2452-2464. PMID: 22427350

  64. Miller, B.S., Ignatoski, K.M., Daignault, S., Lindland, C., Doherty, M., Gauger, P.G., Hammer, G.D., Wang, S.C., Doherty, G.M.; University of Michigan Analytical Morphomics Group. (2012). Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. World Journal of Surgery, 36(7), 1509-1516. PMID: 22526034

  65. Miller, B.S., Gauger, P.G., Hammer, G.D. & Doherty, G.M. (2012). Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery, 152(6), 1150-1157. PMID: 23158185

  66. Heaton, J.H., Wood, M.A., Kim, A.C., Lima, L.O., Barlaskar, F.M., Almeida, M.Q., Fragoso, M.C.B.V., Kuick, R., Lerario, A.M., Simon, D.P., Soares, I.C., Starnes, E., Thomas, D.G., Latronico, A.C., Giordano, T.J. & Hammer, G.D. (2012). Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. The American Journal of Pathology, 181(3),1017-1033. PMID: 22800756

  67. Raymond, V.M., Else, T., Everett, J.N., Long, J.M., Gruber, S.B. & Hammer, G.D. (2013). Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. The Journal of Clinical Endocrinology & Metabolism, 98(1),119-125. PMID: 23175693

  68. França, M.M., Ferraz-de-Souza, B., Santos, M.G., Lerario, A.M., Fragoso, M.C.B.V., Latronico, A.C., Kuick, R.D., Hammer, G.D. & Lotfi, C.F.P. (2013). POD-1 binding to the E-box sequence inhibits SF-1 and StAR expression in human adrenocortical tumor cells. Molecular and Cellular Endocrinology, 371(1-2),140-147. PMID: 23313103

  69. Krill, K.T., Gurdziel, K., Heaton, J.H., Simon, D.P. & Hammer, G.D. (2013). Dicer deficiency reveals micro-RNAs predicted to control gene expression in the developing adrenal cortex. Molecular Endocrinology, 27(5), 754-768. PMID: 23518926

  70. Raymond, V.M., Everett, J.N., Furtado, L.V., Gustafson, S.L., Jungbluth, C.R., Gruber, S.B., Hammer, G.D., Stoffel, E.M., Greenson, J.K., Giordano, T.J. & Else, T. (2013). Adrenocortical carcinoma is a Lynch syndrome associated cancer. Journal of Clinical Oncology, (24), 3012-3018. PMID: 23752102

  71. Wood, M.A., Acharya, A., Finco, I., Swonger, J.M., Elston, M.J., Tallquist, M.D. & Hammer, G.D. (2013). Fetal adrenal capsular cells serve as progenitor cells for steroidogenic and stromal adrenocortical cell lineages in M. musculus. Development, 140(22), 4522-4532. PMID: 24131628

  72. Else, T., Kim, A., Sabolch, A., Raymond, V.M., Kandathil, A., Caoili, E.M., Shruti, J., Miller, B.S., Giordano, T.J. & Hammer, G.D. (2013). Adrenocortical carcinoma. Endocrine Reviews, 35(2), 282-326. PMID: 24423978

  73. Raymond, V.M., Long, J.M., Everett, J.N., Caoili, E.M., Gruber, S.B., Stoffel, E.M., Giordano, T.J., Hammer, G.D. & Else, T. (2013). An oncocytic adrenal tumor in a patient with Birt-Hogg-Dubé syndrome. Clinical Endocrinology (Oxf)., 80(6), 925-927. PMID: 23848572

  74. Lerario, A.M., Moraitis, A. & Hammer, G.D. (2014). Genetics and epigenetics of adrenocortical tumors. Molecular and Cellular Endocrinology, 386(1-2), 67-84. PMID: 24220673

  75. Berruti, A., Fassnacht, M., Haak, H., Else, T., Baudin, E., Sperone, P., Kroiss, M., Kerkhofs, T., Williams, A.R., Ardito, A., Leboulleux, S., Volante, M., Deutschbein, T., Feelders, R., Ronchi, C., Grisanti, S., Gelderblom, H., Porpiglia, F., Papotti, M., Hammer, G.D., Allolio, B. & Terzolo, M. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. (2014). European Urology, 65(4), 832-838. PMID: 24268504

  76. Else, T., Williams, A.R., Sabolch, A., Jolly, S., Miller, B.S. & Hammer, G.D. (2014). Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. The Journal of Clinical Endocrinology & Metabolism, 99(2), 455-461. PMID: 24302750

  77. Subramanian, C., Zhang, H., Gallagher, R., Hammer, G.D., Timmermann, B. & Cohen, M. (2014). Withanolides are potent novel targeted therapeutic agents against adrenocortical carcinomas. World Journal of Surgery, 38(6), 1343-1352. PMID: 24763440

  78. Auchus, R.J., Buschur, E.O., Chang, A.Y., Hammer, G.D., Ramm, C., Madrigal, M., Wang, G., Gonzalez, M., Xu, S., Smit, J.W., Jiao, J. & Yu, M.K. (2014). Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 99(8), 2763-2770. PMID: 24780050

  79. Walczak, E.M., Kuick, R., Finco, I., Bohin, N., Hrycaj, S.M., Wellik, D. & Hammer, G.D. (2014). Wnt-signaling inhibits adrenal steroidogenesis by cell-autonomous and non-cell autonomous mechanisms. Molecular Endocrinology, 28(9), 1471-1486. PMID: 25029241

  80. Williams, A., Hammer, G.D., Else, T. (2014). Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome. European Journal of Endocrinology, 170(6), 829-835. PMID: 24836548

  81. Lerario, A.M., Worden, F.P., Ramm, C.A., Hasseltine, E.A., Stadler, W.M., Else, T., Shah, M.H., Agamah, E., Rao, K. & Hammer, G.D. (2014). The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored Trial. Hormones and Cancer, 5(4), 232–239. PMID: 24849545

  82. Walczak, E.M. & Hammer, G.D. (2015). Regulation of the adrenocortical stem cell niche: implications for disease. Nature Reviews Endocrinology, 11(1), 14-28. PMID: 25287283

  83. Sabolch, A., Else, T., Griffith, K.A., Ben-Josef, E., Williams, A., Miller, B.S., Worden, F., Hammer, G.D., & Jolly, S. (2015). Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. International Journal of Radiation Oncology*Biology*Physics, 92(2), 252-259. PMID: 25754631

  84. Fassnacht, M., Berruti, A., Baudin, E., Demeure, M.J., Gilbert, J., Haak, H., Kroiss, M., Quinn, D.I., Hesseltine, E., Ronchi, C.L., Terzolo, M., Choueiri, T.K., Poondru, S., Fleege, T., Rorig, R., Chen, J., Stephens, A.W., Worden, F. & Hammer, G.D. (2015). Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomized, phase 3 study. Lancet Oncology, 16(4), 426-435. PMID: 25795408

  85. Finco, I., LaPensee, C.R., Krill, K.T. & Hammer, G.D. (2015). Hedgehog signaling and steroidogenesis. The Annual Review of Physiology, 77, 105-129. PMID: 25668018

  86. Xing, Y., Lerario, A.M., Rainey, W. & Hammer, G.D. (2015). Development of adrenal cortex zonation. Endocrinology and Metabolism Clinics of North America, 44(2), 243-274. PMID: 26038200

  87. Nogueira, T.M., Lirov, R., Caoili, E.M., Lerario, A.M., Miller, B.S., Fragoso, M.C.B.V., Dunnick, N.R., Hammer, G.D. & Else, T. (2015). Radiographic characteristics of adrenal masses preceding the diagnosis of adrenocortical cancer. Hormones and Cancer, 6(4), 176-181. PMID: 26021762

  88. Basham, K.J., Hung, H.A., Lerario, A.M. & Hammer, G.D. Mouse models of adrenocortical tumors. Molecular and Cellular Endocrinology, 421, 82-97. PMID: 26678830

  89. Lee, J., Yang, D.J., Lee, S., Hammer, G.D., Kim, K.W. & Elmquist, J.K. (2016). Nutritional conditions regulate transcriptional activity of SF-1 by controlling sumoylation and ubiquitination. Scientific Reports, 6, . PMID: 26750456

  90. Bornstein, S.R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G.D., Husebye, E.S., Merke, D.P., Murad, M.H., Stratakis, C.A., Torpy, D.J. (2016). Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Endocrinology & Metabolism, 101(2), 364-389. PMID: 26760044

  91. LaPensee, C.R., Mann, J.E., Rainey, W.E., Crudo, V., Hunt, S.W. & Hammer, G.D. (2016). ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. Endocrinology, 157(5), 1775-1788. PMID: 26986192

  92. Nanba, K., Chen, A.X., Omata, K., Vinco, M., Giordano, T.J., Else, T., Hammer, G.D., Tomlins, S.A. & Rainey, W.E. (2016). Molecular Heterogeneity in Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology & Metabolism, 101(3), 999-1007. PMID: 26765578
  93. Nanba, K., Omata, K., Tomlins, S.A., Giordano, T.J., Hammer, G.D., Rainey, W.E. & Else, T. (2016). Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA somatic mutations. The European Journal of Endocrinology, 175(2), K1-K6. PMID: 27165862
  94. Zheng, S., Cherniack, A.D., Dewal, N., Moffitt, R.A., Danilova, L., Murray, B.A., Lerario, A.M., Else, T., Knijnenburg, T.A., Ciriello, G., Kim, S., Assie, G., Morozova, O., Akbani, R., Shih, J., Hoadley, K.A., Choueiri, T.K., Waldmann, J., Mete, O., Robertson, A.G., Wu, H.T., Raphael, B.J., Shao, L., Meyerson, M., Demeure, M.J., Beuschlein, F., Gill, A.J., Sidhu, S.B., Almeida, M.Q., Fragoso, M.C., Cope, L.M., Kebebew, E., Habra, M.A., Whitsett, T.G., Bussey, K.J., Rainey, W.E., Asa, S.L., Bertherat, J., Fassnacht, M., Wheeler, D.A., Cancer Genome Atlas Research Network, Hammer, G.D., Giordano, T.J. & Verhaak RG. (2016). Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 29(5), 1-14. PMID: 27505681

  95. Lerario, A.M., Finco, I., LaPensee, C. & Hammer, G.D. (2017). Molecular Mechanisms of Stem/Progenitor Cell Maintenance in the Adrenal Cortex. Frontiers in Endocrinology, 8, 52. PMID: 28386245

  96. Penny, M.K., Finco, I. & Hammer, G.D. (2017). Cell signaling pathways in the adrenal cortex: Links to stem/progenitor biology and neoplasia. Molecular & Cellular Endocrinology, 445, 42-54. PMID: 27940298
  97. Else, T., Lerario, A.M., Everett, J., Haymon, L., Wham, D., Mullane, M., Wilson, T.L., Rainville, I., Rana, H., Worth, A.J., Snyder, N.W., Blair, I.A., McKay, R., Kilbridge, K., Hammer, G.D., Barletta, J. & Vaidya, A. (2017).  Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series. European Journal of Endocrinology, 177(5), 439-444. PMID: 28819017

  98. Xing, Y., Morohashi, K.I., Ingraham, H.A. & Hammer, G.D. (2017). Timing of adrenal regression controlled by synergistic interaction between Sf1 SUMOylation and Dax1. Development, 144(20), 3798-3807. PMID: 28893949

  99. Finco, I., Lerario, A.M. & Hammer GD. (2018). Sonic Hedgehog and WNT Signaling Promote Adrenal Gland Regeneration in Male Mice. Endocrinology, 159(2), 579-596. PMID: 29211850

  100. Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W.K., Luna, A., La, K.C., Dimitriadoy, S., Liu, D.L., Kantheti, H.S., Saghafinia, S., Chakravarty, D., Daian, F., Gao, Q., Bailey, M.H., Liang, W.W., Foltz, S.M., Shmulevich, I., Ding, L., Heins, Z., Ochoa, A., Gross, B., Gao, J., Zhang, H., Kundra, R., Kandoth, C., Bahceci, I., Dervishi, L., Dogrusoz, U., Zhou, W., Shen, H., Laird, P.W., Way, G.P., Greene, C.S., Liang, H., Xiao, Y., Wang, C., Iavarone, A., Berger, A.H., Bivona, T.G., Lazar, A.J., Hammer, G.D., Giordano, T., Kwong, L.N., McArthur, G., Huang, C., Tward, A.D., Frederick, M.J., McCormick, F., Meyerson, M., Cancer Genome Atlas Research Network, Van Allen, E.M., Cherniack, A.D., Ciriello, G., Sander, C., Schultz, N., Van Allen, E.M., Cherniack, A.D., Ciriello, G., Sander, C. & Schultz, N. (2018). Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 173(2), 321-337.e10. PMID: 29625050 

  101. Finco, I. & Hammer, G.D. (2018). Isolation, Fixation, and Immunofluorescence Imaging of Mouse Adrenal Glands. Journal of Visualized Experiments, (140), 58530. PMID: 30346404 

  102. Mohan, D.R., Lerario, A.M. & Hammer, G.D. (2018). Therapeutic Targets for Adrenocortical Carcinoma in the Genomics Era. Journal of the Endocrine Society, 2(11), 1259-1274. PMID: 30402590

  103. Lerario, A.M. & Hammer, G.D. (2018). Drug repurposing using high-throughput screening identifies a promising drug combination to treat adrenocortical carcinoma. Oncotarget, 9(70), 33245-33246. PMID: 30279954

  104. Glenn, J.A., Else, T., Hughes, D.T., Cohen, M.S., Jolly, S., Giordano, T.J., Worden, F.P., Gauger, P.G., Hammer, G.D. & Miller, B.S. (2019). Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. Surgery, 165(1), 186-195. PMID: 30343951

  105. Mouat, I.C., Omata, K., McDaniel, A.S., Hattangady, N.G., Talapatra, D., Cani, A.K., Hovelson, D.H., Tomlins, S.A., Rainey, W.E., Hammer, G.D., Giordano, T.J. & Else T. (2019). Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism. Endocrine-Related Cancer, 26(2), 217-225. PMID: 30475217

  106. Basham, K.J., Rodriguez, S., Turcu, A.F., Lerario, A.M., Logan, C.J., Rysztak, M.R., Gomez-Sanchez, C.E., Breault, D.T., Koo, B-K., Clevers, H., Nusse, R., Val, P. & Hammer, G.D. (2019). ZNRF3-dependent Wnt/β-catenin signaling gradient is required for adrenal homeostasis. Genes & Development, 33(3-4), 209-220. PMID: 30692207

  107. Mohan, D.R., Lerario, A.M., Else, T., Mukherjee, B., Almeida, M., Vinco, M., Rege, J., Mariani, B., Zerbini, M., Mendonca, B., Latronico, A., Marie, S., Rainey, W., Giordano, T., Fragoso, M. & Hammer, G.D. (2019). Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. Clinical Cancer Research, 25(11), 3276-3288. PMID: 30770352

  108. Gharzai, L.A., Green, M.D., Griffith, K.A., Else, T., Mayo, C.S., Hesseltine, E., Spratt, D.E., Ben-Josef, E., Sabolch, A., Miller, B.A., Worden, F., Giordano, T., Hammer, G.D. & Jolly, S. (2019). Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. Journal of Clinical Endocrinology & Metabolism, 104(9), 3743-3750. PMID: 31220287

  109. Finco, I., Mohan, D.R., Hammer, G.D. & Lerario, A.M. (2019). Regulation of stem and progenitor cells in the adrenal cortex. Current Opinion in Endocrine & Metabolic Research, 8, 66-71. PMID: 32258821

  110. Mohan, D.R., Lerario, A.M., Finco, I. & Hammer, G.D. (2019). New strategies for applying targeted therapies to adrenocortical carcinoma. Current Opinion in Endocrine & Metabolic Research, 8, 72-79. PMID: 32258822 

  111. Plaska, S.W., Liu, C-J., Lim, J.S., Rege, J., Bick, N.R., Lerario, A.M., Hammer, G.D., Giordano, T.J., Else, T., Tomlins, S.A., Rainey, W.E. & Udager, A.M. (2020). Targeted RNAseq of Formalin-Fixed Paraffin-Embedded Tissue to Differentiate Among Benign and Malignant Adrenal Cortical Tumors. Hormone & Metabolic Research, 52(8), 607-613. PMID: 32791542
  112. Hammer, G.D. & Basham, K.J. (2021). Stem cell function and plasticity in the normal physiology of the adrenal cortex. Molecular and Cellular Endocrinology, 519, 111043. PMID: 33058950
  113. Little, D.W. 3rd, Dumontet, T., LaPensee, C.R. & Hammer, G.D. (2021). β-catenin in adrenal zonation and disease. Molecular and Cellular Endocrinology, 522, 111120. PMID: 33338548
  114. Juhlin, C.C., Bertherat, J., Giordano, T.J., Hammer, G.D., Sasano, H. & Mete, O. (2021). What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics. Endocrine Pathology, 32(1), 102-133. PMID: 33534120
  115. Dumontet, T. & Hammer, G.D. (2022). Bones and adrenal organogenesis: how embryonic osteocalcin influences lifelong adrenal function. The Journal of Clinical Investigation, 132(4), e157200. PMID:35166237

  116. Yip, L., Duh, Q-Y., Wachtel, H., Jimenez, C., Sturgeon, C., Lee, C., Velázquez-Fernández, D., Berber, E., Hammer, G.D., Bancos, I., Lee, J.A., Marko, J., Morris-Wiseman, L.F., Hughes, M.S., Livhits, M.J., Han, M-A., Smith, P.W., Wilhelm, S., Asa, S.L., Fahey, T.J. 3rd, McKenzie, T.J., Strong, V.E. & Perrier, N.D. (2022). American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary. JAMA Surgery, 157(10), 870-877. PMID: 35976622

  117. Lerario, A.M., Mohan, D.R. & Hammer, G.D. (2022). Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies. Endocrine Reviews, 43(6), 1051-1073. PMID: 35551369

  118. Warde, K.M., Smith, L.J., Liu, L., Stubben, C.J., Lohman, B.K., Willett, P.W., Ammer, J.L., Castaneda-Hernandez, G., Imodoye, S.O., Zhang, C., Jones, K.D., Converso-Baran, K., Ekiz, H.A., Barry, M., Clay, M.R., Kiseljak-Vassiliades, K., Giordano, T.J., Hammer, G.D. & Basham, K.J. (2023). Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner. Nature Aging, 3(7), 846-865. PMID: 37231196

  119. Penny, M.K., Lerario, A.M., Basham, K.J., Chukkapalli, S., Mohan, D.R., LaPensee, C., Converso-Baran, K., Hoenerhoff, M.J., Suárez-Fernández, L., Gonzalez Del Rey, C., Giordano, T.J., Han, R., Newman, E.A. & Hammer, G.D. (2023). Targeting Oncogenic Wnt/β-Catenin Signaling in Adrenocortical Carcinoma Disrupts ECM Expression and Impairs Tumor Growth. Cancers (Basel), 15(14), 3559. PMID: 37509222                                                                                                                                                          

  120. Mohan, D.R., Borges, K.S., Finco, I., LaPensee, C.R., Rege, J., Solon, A.L., Little, D.W., Else, T., Almeida, M.Q., Dang, D., Haggerty-Skeans, J., Apfelbaum, A.A., Vinco, M., Wakamatsu, A., Mariani, B.M.P., Amorim, L.C., Latronico, A.C., Mendonca, B.B., Zerbini, M.C.N., Lawlor, E.R., Ohi, R., Auchus, R.J., Rainey, W.E., Marie, S.K.N., Giordano, T.J., Venneti, S., Fragoso, M.C.B.V., Breault, D.T., Lerario, A.M. & Hammer, G.D. (2023). β-Catenin-Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer. Cancer Research, 83(13), 2123-2141. PMID: 37129912

  121. Cheung, L.Y.M., Menage, L., Rizzoti, K., Hamilton, G., Dumontet, T., Basham, K., Daly, A.Z., Brinkmeier, M.L., Masser, B.E., Treier, M., Cobb, J., Delogu, A., Lovell-Badge, R., Hammer, G.D. & Camper, S.A. (2023). Novel Candidate Regulators and Developmental Trajectory of Pituitary Thyrotropes. Endocrinology, 164(6). PMID: 37183548

  122. Gulbins, A., Horstmann, M., Keitsch, S., Soddemann, M., Wilker, B., Wilson, G.C., Zeidan, R., Hammer, G.D., Daser, A., Bechrakis, N.E., Görtz, G.E. & Eckstein, A. (2023). Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease. Frontiers in Endocrinology (Lausanne), PMID: 37810891

  123. Gulbins, A., Horstmann, M., Daser, A., Flögel, U., Oeverhaus, M., Bechrakis, N.E., Banga, J.P., Keitsch, S., Wilker, B., Krause, G., Hammer, G.D., Spencer, A.G., Zeidan, R., Eckstein, A., Philipp, S. & Görtz, G.E. (2023). Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. Frontiers in Endocrinology (Lausanne), 14, 1211473. PMID: 37435490

  124. LaPensee, C.R. & Hammer, G.D. (2023). Targeting of a New Node in Lipid Metabolism as a Potential Treatment Strategy for ACC. Endocrinology, 164(3), bqad003. PMID: 36636840

  125. van Rooyen, D., Lerario, A.M., Little, D.W. 3rd, Ullenbruch, M.R., Taylor, M.J., Gomez-Sanchez, C.E., Hammer, G.D. & Rainey, W.E. (2024). Chronic activation of adrenal Gq signaling induces Cyp11b2 expression in the zona fasciculata and hyperaldosteronism. Molecular and Cellular Endocrinology, 585, 112176. PMID: 38341019

  126. Chu, Y., Setayesh, J., Dumontet, T., Krumeich, L., Werner, J., Moretti, I.F., De Sousa, K., Kennedy, C., La Pensee, C., Lerario, A.M. & Hammer, G.D. (2025). Adrenocortical stem cells in health and disease. Nature Reviews Endocrinology, 21(8), 464-481. PMID: 40065108

  127. Chan, Y.S., Gao, O., Robinson, S.A., Wang, W., Filandrova, R., Weinhold, L-M., Cabrera, M.L., Zhang, M., Shekar, C., Ambati, R., Marcondes Lerario, A., Putluri, N., Kiseljak-Vassiliades, K., Wierman, M.E., Habra, M.A., Hammer, G.D., Veverka, V., Cermakova, K. & Hodges, H.C. (2025). β-catenin functions as a molecular adapter for disordered cBAF interactions. Molecular Cell, 85(16), 3041- 3056. PMID: 40695292

  128. Dumontet, T., Basham, K.J., Foster, M.C., Silverman, E., Heard, K.A., Johnson, D., Lee, C., Plaska, S.W., Breault, D.T., Penton, D., Beuschlein, F., Turcu, A.F., LaPensee, C.R., Marcondes Lerario, A. & Hammer, G.D. (2025). The transcription factor HHEX maintains glucocorticoid levels and protects adrenals from androgen-induced lipid depletion. Nature Communications, PMID: 40321776.

  129. Sinha, A., Wolf, K.I., Osborne, J., Hesseltine, E.A., Worden, F.P., Giordano, T.J., Hammer, G.D. & Else, T. (2026). Prevalence and Clinical Characteristics of Lynch Syndrome-associated Adrenocortical Carcinoma. Endocrine Related Cancer, PMID: 41524568.

  130. Wolf, K.I., Osborne, J., Lerario, A.M., Vo, J.N., Hamidi, O., Habra, M.A., Hammer, G.D. & Else, T. (2026). Adrenocortical carcinoma as a manifestation of Birt-Hogg Dube Syndrome. Endocrine Related Cancer, [Accepted].